Biotech Values

[zipjet]

MNTA has a long way to go to be near 10s of alternative biotech stocks. I still think that it is possible, but it surely has been a relative loser compared to the spectacular returns available in BIIB and many others.

Even ARIA is up over 150% from the recent lows. (I kept buying to almost the low.)

Or GENT which is up close to 600% from June. (GENT was in my contest picks. But better yet, I own it.)

At one time MNTA was my largest position. Lost interest and sold it. It is again interesting. I suspect they will get gCopaxone approval and it may come soon. The question is what value the market will accord the approval. The last approval very disappointing.